HAS Healthcare Advanced Synthesis SA showcases in the upcoming 2024 CPhI Japan trade show in Tokyo
HAS Healthcare Advanced Synthesis SA (“HAS”), a full-service contract development and manufacturing organization (CDMO) delivering high-quality, exclusive, personalized solutions to its healthcare clients, today announces its participation as exhibitor in the 2024 CPhI Japan trade show that will be hosted in Tokyo Big Sight, on 17 – 19 April 2024.
CPhI Japan offers an unparalleled gateway to the Japanese Pharma market, and helps create connections with suppliers, innovators and industry leaders and inspires partnerships across the global pharma community.
Our Booth 5Q-11, will feature our products and services. We will showcase our cutting-edge contracting manufacturing facilities based in the south of Switzerland, which provide exclusive, customized, innovative, and technology-advanced, high-quality solutions for pharma and biotech companies.
At HAS, we are passionate about tailoring our services to our clients’ clinical and commercial manufacturing needs and going the extra mile to support them with their analytical and regulatory requirements. We prioritize sustainability and ethical practices. We strive to create positive impacts on both our community and the planet.
We proudly specialize in the delivery of oncology and rare disease compounds and hold a strong track record in reducing time to market for life- saving products in these areas.
All this keeps us at the forefront of the global pharmaceutical industry.
Join us at our booth and be part of the future of pharma, where innovation and life-changing breakthroughs await.
If you cannot make it to Japan, connect to our website and learn more on how we offer the best CDMO standards as a full-service partner to our healthcare clients: www.hashealthcare.com and follow us on Linkedin.
About HAS
HAS Healthcare Advanced Synthesis is a CDMO that offers a full range of customized services from laboratory development to manufacturing. HAS Healthcare Advanced Synthesis develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, and high-activity active pharmaceutical ingredients (HPAPIs).
The production facility is located in Biasca, Switzerland, and was founded in 1984. The site is regularly inspected by SwissMedic, the FDA and other global regulatory agencies. The production scale ranges from a few hundred grams to tens of kilograms for highly active ingredients (HPAPI) and anticancer and from kilograms to tens of tons for standard active ingredients (APIs); the plants are completely dedicated to cGMP production.
For more information visit our website https://www.hashealthcare.com/ and follow us on Linkedin
Contact Press Office
HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]